ABT-199 ≥98%|CAS:1257044-40-8|1 mg|5 mg|10 mg

GDC-0199|ABT-199 is a BH3 mimetic that inhibits Bcl-2 but does not affect Bcl-xl. ABT-199 exhibits anticancer chemotherapeutic activity, inducing Bim-mediated apoptosis in chronic lymphocytic leukemia (CLL) cells. ABT-199 also induces cell death and inhibits tumor growth in acute myelogenous leukemia (AML) models in vitro, ex vivo, and in vivo. ABT-199 is currently under examination as a potential treatment for CLL.|C45H50ClN7O7S|868.44||+4°C|Soluble in DMSO.